Manuel Franco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Manuel Franco has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Juan Raúl Castro-Ayarza
Dermatology Postgraduate Program, Faculty of Medicine, National University of Colombia, Bogota, Colombia
7 shared publications - Angela María Londoño-García
CES University Medellin Colombia
5 shared publications - Cesar Fernando González Ardila
Private Practice, Bogota, Colombia
5 shared publications - Carolina Cortés Correa
Hospital Universitario de la Samaritana, Bogotá, Colombia
4 shared publications - Julieth Carolina Castillo
Epidemiology Department, Epithink Health Consulting, Bogotá, Colombia
4 shared publications - Linda Ibatá
EpiThink Health Consulting Bogotá Colombia
4 shared publications
Latest Publications
- Open Access
- 29 August 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (5)
Clinical practice guideline for psoriasis management in Latin America
- 29 August 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (5)
Open AccessClinical practice guideline for psoriasis management in Latin America
- 10 July 2026
- Published by Wiley in International Journal of Dermatology
Treat‐To‐Target Goals for Atopic Dermatitis in Colombia: A Modified Delphi Consensus From the Colombian Group of Psoriasis and Immunodermatology ( COLPSOR )
Atopic dermatitis causes substantial symptom burden and impaired quality of life. Treat‐to‐target strategies can improve care by linking management decisions to explicit therapeutic goals, but Colombia lacks a consensus framework for routine practice. We conducted a modified Delphi consensus with 22 Colombian specialists in atopic dermatitis. Two anonymous voting rounds were informed by a systematic literature review. Governance safeguards, conflict‐of‐interest management, and sponsor noninvolvement were prespecified. Main targets and timelines were classified with a simplified evidence‐level and recommendation‐strength framework. The panel defined acceptable and optimal therapeutic targets using clinician‐reported measures and patient‐reported outcome measures. Eczema Area and Severity Index (EASI)‐based thresholds and core symptom and quality‐of‐life instruments were supported by higher‐quality evidence, whereas follow‐up intervals, implementation strategies, and some adjunct measures relied more on expert consensus and contextual adaptation. The framework links response thresholds to reassessment timelines and treatment decisions for routine care. This consensus provides a practical treat‐to‐target framework for atopic dermatitis in Colombia and a model that may inform adaptation in other health systems. image
- 10 July 2026
- Published by Wiley in International Journal of Dermatology
Treat‐To‐Target Goals for Atopic Dermatitis in Colombia: A Modified Delphi Consensus From the Colombian Group of Psoriasis and Immunodermatology ( COLPSOR )
Atopic dermatitis causes substantial symptom burden and impaired quality of life. Treat‐to‐target strategies can improve care by linking management decisions to explicit therapeutic goals, but Colombia lacks a consensus framework for routine practice. We conducted a modified Delphi consensus with 22 Colombian specialists in atopic dermatitis. Two anonymous voting rounds were informed by a systematic literature review. Governance safeguards, conflict‐of‐interest management, and sponsor noninvolvement were prespecified. Main targets and timelines were classified with a simplified evidence‐level and recommendation‐strength framework. The panel defined acceptable and optimal therapeutic targets using clinician‐reported measures and patient‐reported outcome measures. Eczema Area and Severity Index (EASI)‐based thresholds and core symptom and quality‐of‐life instruments were supported by higher‐quality evidence, whereas follow‐up intervals, implementation strategies, and some adjunct measures relied more on expert consensus and contextual adaptation. The framework links response thresholds to reassessment timelines and treatment decisions for routine care. This consensus provides a practical treat‐to‐target framework for atopic dermatitis in Colombia and a model that may inform adaptation in other health systems. image
- 1 June 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (Suppl 2) , 12-14
Topicals for Psoriasis: Classical Drugs, New Concepts, and New Medications
Psoriasis is a chronic, immune-mediated disease affecting the skin. Its prevalence varies by region (0.2-9%), and some patients may develop joint involvement. For mild disease, and as adjuncts in moderate disease, topical therapies remain the foundation of care. Classical agents include topical corticosteroids and vitamin D analogs. Other legacy options (tazarotene, salicylic acid, coal tar, and calcineurin inhibitors) serve as adjuvants with variable efficacy. Recent advances have led to new targeted nonsteroidal topicals such as tapinarof (aryl hydrocarbon receptor agonist) and roflumilast (phosphodiesterase 4 inhibitor). We summarize evidence, propose practical prescribing recommendations for nondermatologists, and position new agents within a steroid-sparing, precision framework. A persistent challenge is affordability, in which high acquisition costs for novel topicals may restrict real-world access unless supported by pricing and reimbursement policies. This work was presented at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 annual meeting in Bogotá as a concurrent session.
- 1 June 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (Suppl 2) , 12-14
Topicals for Psoriasis: Classical Drugs, New Concepts, and New Medications
Psoriasis is a chronic, immune-mediated disease affecting the skin. Its prevalence varies by region (0.2-9%), and some patients may develop joint involvement. For mild disease, and as adjuncts in moderate disease, topical therapies remain the foundation of care. Classical agents include topical corticosteroids and vitamin D analogs. Other legacy options (tazarotene, salicylic acid, coal tar, and calcineurin inhibitors) serve as adjuvants with variable efficacy. Recent advances have led to new targeted nonsteroidal topicals such as tapinarof (aryl hydrocarbon receptor agonist) and roflumilast (phosphodiesterase 4 inhibitor). We summarize evidence, propose practical prescribing recommendations for nondermatologists, and position new agents within a steroid-sparing, precision framework. A persistent challenge is affordability, in which high acquisition costs for novel topicals may restrict real-world access unless supported by pricing and reimbursement policies. This work was presented at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 annual meeting in Bogotá as a concurrent session.
- 1 September 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (Suppl 3) , 19-22
Diagnosis and Assessment of Psoriasis for the Rheumatologist: A Workshop From the GRAPPA 2024 Annual Meeting
Rheumatologists and other nondermatologists often encounter patients with psoriatic arthritis (PsA) who present with cutaneous diseases that mimic psoriasis (PsO). Cutaneous disorders including tinea, seborrheic dermatitis, eczema, pityriasis rubra pilaris, syphilis, or cutaneous lymphoma are commonly mistaken for PsO. It is crucial for rheumatologists and other nondermatologists to recognize alternative conditions and to consider referral to dermatology when skin disease is not responding to therapy. Correct diagnosis is important when assessing disease severity in clinical practice as well. Although the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI) are gold standards for physician- and patient-reported outcomes in clinical trials, they are not practical to deploy in busy clinical practice. Use of a physician global assessment (PGA), body surface area using a handprint method, and informal patient-reported outcomes can be useful in documenting the burden of disease. A treat-to-target approach using a PGA of clear/almost clear is ideal. At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting, a 2-part workshop was conducted for rheumatologists to first review skin disorders commonly mistaken for PsO, and second, to review outcome measures best suited for clinical practice.
- 1 September 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (Suppl 3) , 19-22
Diagnosis and Assessment of Psoriasis for the Rheumatologist: A Workshop From the GRAPPA 2024 Annual Meeting
Rheumatologists and other nondermatologists often encounter patients with psoriatic arthritis (PsA) who present with cutaneous diseases that mimic psoriasis (PsO). Cutaneous disorders including tinea, seborrheic dermatitis, eczema, pityriasis rubra pilaris, syphilis, or cutaneous lymphoma are commonly mistaken for PsO. It is crucial for rheumatologists and other nondermatologists to recognize alternative conditions and to consider referral to dermatology when skin disease is not responding to therapy. Correct diagnosis is important when assessing disease severity in clinical practice as well. Although the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI) are gold standards for physician- and patient-reported outcomes in clinical trials, they are not practical to deploy in busy clinical practice. Use of a physician global assessment (PGA), body surface area using a handprint method, and informal patient-reported outcomes can be useful in documenting the burden of disease. A treat-to-target approach using a PGA of clear/almost clear is ideal. At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting, a 2-part workshop was conducted for rheumatologists to first review skin disorders commonly mistaken for PsO, and second, to review outcome measures best suited for clinical practice.
- Open Access
- 30 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (3) , 539-547
Consenso latino‐americano sobre classificação da gravidade da psoríase
- 30 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (3) , 539-547
Open AccessConsenso latino‐americano sobre classificação da gravidade da psoríase
- Open Access
- 29 April 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (3) , 539-547
Latin American consensus on psoriasis severity classification
- 29 April 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (3) , 539-547
Open AccessLatin American consensus on psoriasis severity classification
- Open Access
- 7 January 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (1) , e16774
A Case Series of a Novel Approach in the Treatment of Rosacea: Use of Botulinum Toxin and Intense Pulsed Light for the Treatment of Erythematotelangiectatic Rosacea
- 7 January 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (1) , e16774
Open AccessA Case Series of a Novel Approach in the Treatment of Rosacea: Use of Botulinum Toxin and Intense Pulsed Light for the Treatment of Erythematotelangiectatic Rosacea
- Open Access
- 19 January 2024
- Published by Asociacion Colombiana de Dermatologia y Cirugia Dermatologica in Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
- Vol. 31 (3) , 212-217
Reporte de caso: alopecia areata universal tratada exitosamente con baricitinib
La alopecia areata es una enfermedad dermatológica caracterizada por la pérdida de pelo, no cicatricial, y de origen autoinmune, que afecta aproximadamente al 2% de la población [1,2]. Es una enfermedad multifactorial, con predisposición genética, asociado a factores desencadenantes (psicológicos y estrés) y otras enfermedades inmunomediadas (tiroiditis, vitiligo). Su presentación clínica más habitual es la aparición de una o varias placas de alopecia en cuero cabelludo, barba, cejas o pestañas, bien definidas, con signo de tracción presente en los bordes poblados de pelo en las lesiones, además de pelos en “signo de exclamación” sobre el área alopécica (1,2,4). Existe gran variedad de tratamientos tanto locales como sistémicos, sin embargo, poco efectivos a largo plazo y con elevado riesgo adverso al mantener la terapia. Nuevas estrategias de tratamiento han surgido como los inhibidores selectivos de la janus quinasa, prometedores para el tratamiento de la alopecia areata a largo plazo. Presentamos a continuación un caso de alopecia areata universal tratado exitosamente con Baricitinib.
- 19 January 2024
- Published by Asociacion Colombiana de Dermatologia y Cirugia Dermatologica in Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
- Vol. 31 (3) , 212-217
Open AccessReporte de caso: alopecia areata universal tratada exitosamente con baricitinib
La alopecia areata es una enfermedad dermatológica caracterizada por la pérdida de pelo, no cicatricial, y de origen autoinmune, que afecta aproximadamente al 2% de la población [1,2]. Es una enfermedad multifactorial, con predisposición genética, asociado a factores desencadenantes (psicológicos y estrés) y otras enfermedades inmunomediadas (tiroiditis, vitiligo). Su presentación clínica más habitual es la aparición de una o varias placas de alopecia en cuero cabelludo, barba, cejas o pestañas, bien definidas, con signo de tracción presente en los bordes poblados de pelo en las lesiones, además de pelos en “signo de exclamación” sobre el área alopécica (1,2,4). Existe gran variedad de tratamientos tanto locales como sistémicos, sin embargo, poco efectivos a largo plazo y con elevado riesgo adverso al mantener la terapia. Nuevas estrategias de tratamiento han surgido como los inhibidores selectivos de la janus quinasa, prometedores para el tratamiento de la alopecia areata a largo plazo. Presentamos a continuación un caso de alopecia areata universal tratado exitosamente con Baricitinib.
- Open Access
- 8 February 2023
- Published by Asociacion Colombiana de Dermatologia y Cirugia Dermatologica in Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
- Vol. 30 (2)
Tecnología en dermatología: ¿Dónde estamos y hacia dónde vamos?
La dermatología no está exenta de los desarrollos tecnológicos que están ocurriendo y los cuales muchas veces damos por sentado que siempre han estado allí. El simple uso de la historia clínica electrónica realizada en computadores y almacenada en la gigantesca plataforma informativa que hoy llamamos “nube”, que nos permite tener fotos y seguimientos de acceso inmediato.
- 8 February 2023
- Published by Asociacion Colombiana de Dermatologia y Cirugia Dermatologica in Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
- Vol. 30 (2)
Open AccessTecnología en dermatología: ¿Dónde estamos y hacia dónde vamos?
La dermatología no está exenta de los desarrollos tecnológicos que están ocurriendo y los cuales muchas veces damos por sentado que siempre han estado allí. El simple uso de la historia clínica electrónica realizada en computadores y almacenada en la gigantesca plataforma informativa que hoy llamamos “nube”, que nos permite tener fotos y seguimientos de acceso inmediato.
- Open Access
- 13 July 2022
- Published by Asociacion Colombiana de Dermatologia y Cirugia Dermatologica in Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
Guía de práctica clínica para el tratamiento de la psoriasis en Colombia
El desarrollo científico en medicina y los recientes avances biotecnológicos exigen la necesidad de actualización permanente de las directrices para incorporar a la práctica clínica la mejor evidencia disponible para obtener los mejores resultados en los pacientes.¹ En concordancia, este documento actualiza el documento publicado en 2018 de la guía de práctica clínica para el tratamiento de la psoriasis en Colombia, de la Asociación Colombiana de Dermatología y Cirugía Dermatológica (AsoColDerma).Las preguntas no actualizadas de la guía junto con la evidencia pueden ser consultadas en la guía de práctica clínica para el tratamiento de la psoriasis en Colombia, publicada en 2018 y que se encuentra disponible en:https://revista.asocolderma.org.co/index.php/asocolderma/article/view/1507
- 13 July 2022
- Published by Asociacion Colombiana de Dermatologia y Cirugia Dermatologica in Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
Open AccessGuía de práctica clínica para el tratamiento de la psoriasis en Colombia
El desarrollo científico en medicina y los recientes avances biotecnológicos exigen la necesidad de actualización permanente de las directrices para incorporar a la práctica clínica la mejor evidencia disponible para obtener los mejores resultados en los pacientes.¹ En concordancia, este documento actualiza el documento publicado en 2018 de la guía de práctica clínica para el tratamiento de la psoriasis en Colombia, de la Asociación Colombiana de Dermatología y Cirugía Dermatológica (AsoColDerma).Las preguntas no actualizadas de la guía junto con la evidencia pueden ser consultadas en la guía de práctica clínica para el tratamiento de la psoriasis en Colombia, publicada en 2018 y que se encuentra disponible en:https://revista.asocolderma.org.co/index.php/asocolderma/article/view/1507